Navigation Links
Taiho Pharmaceutical Announces Results of Randomized Phase II Clinical Trial with Novel Antitumor Agent TAS-102
Date:7/22/2011

TOKYO, July 22, 2011 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Toru Usami) announced on July 22 the results of a randomized, Phase II clinical trial for the novel oral nucleoside antitumor agent TAS-102 under development by the company for metastatic colorectal cancer, at the 9th Annual Meeting of the Japanese Society of Medical Oncology held in Yokohama. (Abstract no. 10428)

The trial was a randomized, double-blind, placebo-controlled study with a primary outcome measure of overall survival involving 172 patients with refractory metastatic colorectal cancer who had received standard chemotherapy at least two or more regimens containing a fluoropyrimidine, irinotecan, and oxaliplatin. The results indicated that the TAS-102 significantly improved overall survival compared with the placebo (overall survival median: 9.0 months vs. 6.6 months) and significantly reduced the risk of mortality (HR=0.56, p=0.0011). Also, no instances of treatment-related mortality were reported. The most frequently reported adverse drug reaction with a CTCAE grade 3 or higher was neutropenia. Grade 3 or higher diarrhea, fatigue, nausea, and other adverse reactions were no more than 10%.

In light of these results, Taiho Pharmaceutical will proceed with global development of TAS-102 so that this drug can be offered as soon as possible to metastatic colorectal cancer patients who have exhausted proven treatment options and there remains a high unmet medical need.

About TAS-102:

TAS-102 is a novel oral nucleoside antitumor agent with a novel mechanism of action, composed of a mixture of Trifluorothymidine (FTD), which demonstrates antitumor effects through incorporation into DNA, and 5-chloro-6-(2-iminopyrrolidin-1-yl)-methyl-2,4(1H,3H)-pyrimidinedione hydrochloride (TPI), which inhibits the degradation of FTD. Phase I trials began in Japan in 2005, and the drug continues to be developed as a treatment for colorectal cancer refra
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  In any given hospital ... 25 patients has at least one hospital-acquired infection, according ... more, many of these infections prove fatal. And as ... alarming number of patient deaths per year, infection control ... Consequently, a stronger emphasis is being ...
(Date:7/24/2014)... DALLAS , July 24, 2014 /PRNewswire-iReach/ -- ... days once order is placed. Photo ... is a professional and in-depth market survey on ... firstly reviews the basic information of Hemodialysis Machine ... report then explores global and China,s top manufacturers ...
(Date:7/24/2014)... -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) today ... 2014. Three Months Ended 06/30/14Three Months Ended 06/30/13 ,  Percentage ... 51% Non-GAAP Net Sales , $278.8 Million , $196.1 ... , $1.12 , 37% Non-GAAP Diluted ... 37%  Six Months Ended 06/30/14Six Months Ended 06/30/13 , ...
Breaking Medicine Technology:Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Questcor Reports Record Second Quarter Financial Results 2Questcor Reports Record Second Quarter Financial Results 3Questcor Reports Record Second Quarter Financial Results 4Questcor Reports Record Second Quarter Financial Results 5Questcor Reports Record Second Quarter Financial Results 6Questcor Reports Record Second Quarter Financial Results 7Questcor Reports Record Second Quarter Financial Results 8Questcor Reports Record Second Quarter Financial Results 9Questcor Reports Record Second Quarter Financial Results 10Questcor Reports Record Second Quarter Financial Results 11Questcor Reports Record Second Quarter Financial Results 12Questcor Reports Record Second Quarter Financial Results 13Questcor Reports Record Second Quarter Financial Results 14Questcor Reports Record Second Quarter Financial Results 15Questcor Reports Record Second Quarter Financial Results 16Questcor Reports Record Second Quarter Financial Results 17Questcor Reports Record Second Quarter Financial Results 18Questcor Reports Record Second Quarter Financial Results 19Questcor Reports Record Second Quarter Financial Results 20Questcor Reports Record Second Quarter Financial Results 21Questcor Reports Record Second Quarter Financial Results 22Questcor Reports Record Second Quarter Financial Results 23Questcor Reports Record Second Quarter Financial Results 24Questcor Reports Record Second Quarter Financial Results 25Questcor Reports Record Second Quarter Financial Results 26Questcor Reports Record Second Quarter Financial Results 27Questcor Reports Record Second Quarter Financial Results 28
... WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS ... today announced that it has appointed world-renowned clinical genomics ... Scientific Advisory Board.   Dr. Chinnaiyan is ... the clinic to choose appropriate therapies for cancer patients. ...
... SAN DIEGO, Jan. 19, 2011 ADVENTRX Pharmaceuticals, Inc. (NYSE ... Food and Drug Administration (FDA) has established a Prescription Drug ... the review of the Exelbine (ANX-530) New Drug Application (NDA). ... that the application is sufficiently complete to permit a substantive ...
Cached Medicine Technology:WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board 2WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board 3WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board 4ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA 2ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA 3
(Date:7/25/2014)... Texas (PRWEB) July 25, 2014 Yisrayl Hawkins, ... Texas, is once again stirring the pot by revealing to ... they are deceived into worshipping Satan, the devil, in his ... clever plan organized by Satan, and carried out by the ... of the Creator from the Inspired Holy Scriptures and replacing ...
(Date:7/25/2014)... 2014 According to the Liver ... by Vkool.com, this is a comprehensive guide that ... and safe remedies for liver cirrhosis . ...     Chapter 1: Liver Cirrhosis Bible ... Learn About Liver Basics ,     Chapter 3: ...
(Date:7/24/2014)... July 25, 2014 iFitDress.com, a renowned ... new range of casual party dresses . According ... party gowns are now offered at discounted prices, up ... this morning until August 04. , Most of ... in the global market. They are popular for special ...
(Date:7/24/2014)... nighttime production of the hormone melatonin, renders breast cancer ... drug, says a new study by Tulane University School ... Disruption by Exposure to Light at Night Drives Intrinsic ... the journal Cancer Research , is the first ... of tamoxifen in treating breast cancer. , , Principal ...
(Date:7/24/2014)... The report, “Content Delivery Networks (CDN) Market”, ... sub-segments with an in-depth analysis and forecasting of ... for this market with insights on trends, opportunities, ... and 36 figures spread through 157 pages and ... at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . , Early buyers ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Says You Have Been Tricked Into Worshipping Satan in New Article 2Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 2Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 3Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4
... Therapy for Cardiovascular Disease (IC3D) is a three-day ... cell-based therapies for treating cardiovascular diseases. The theme ... Building Blocks: Strategies for Cardiovascular Reconstruction in 2009." ... present basic, core discussions on stem cell science ...
... our troops" is no longer just,a slogan -- it,s ... and a,new marketing campaign for the renamed Bob ... JWT Atlanta., By focusing on the physical and ... and raising money to provide,resources and support for injured ...
... for Invisicare Is Put In Place, LAS ... SKVI), the developers of Invisicare, a patented polymer,delivery ... appointment of Geert Cauwenbergh, PhD to head its ... to expand the demand,for Invisicare in international markets. ...
... HOUSTON, Nov. 6 US Oncology, Inc. ("US Oncology" ... services companies,reported revenue of $821.7 million, EBITDA of $54.5 ... million and operating cash flow,of $35.1 million for the ... ended September 30, 2008, US Oncology reported revenue of ...
... MOUNT LAUREL, N.J., Nov. 6 At ... Inc. (Nasdaq: MEDQ ) is introducing ... top-ranked,interactive front-end speech recognition application, and RadWorkFlow(R), ... RadWorkFlow offers an efficient, simplified, and ...
... LIMS System Chosen by Hospital to Replace ... Global Med Technologies(R),Inc. ("Global Med" or ... e-Health, medical information technology company, today,announced that ... Laboratory,Information Management Software (marketed as "Labo Serveur" ...
Cached Medicine News:Health News:5th Annual Global Conference on Stem Cell Therapy to be held Jan. 13-16, 2009 in NYC 2Health News:Bob Woodruff Foundation and JWT Introduce Marketing Campaign and Unveil www.ReMIND.org 2Health News:Bob Woodruff Foundation and JWT Introduce Marketing Campaign and Unveil www.ReMIND.org 3Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 2Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 3Health News:US Oncology Reports Third Quarter 2008 Results 2Health News:US Oncology Reports Third Quarter 2008 Results 3Health News:US Oncology Reports Third Quarter 2008 Results 4Health News:US Oncology Reports Third Quarter 2008 Results 5Health News:US Oncology Reports Third Quarter 2008 Results 6Health News:US Oncology Reports Third Quarter 2008 Results 7Health News:US Oncology Reports Third Quarter 2008 Results 8Health News:US Oncology Reports Third Quarter 2008 Results 9Health News:US Oncology Reports Third Quarter 2008 Results 10Health News:US Oncology Reports Third Quarter 2008 Results 11Health News:US Oncology Reports Third Quarter 2008 Results 12Health News:US Oncology Reports Third Quarter 2008 Results 13Health News:US Oncology Reports Third Quarter 2008 Results 14Health News:US Oncology Reports Third Quarter 2008 Results 15Health News:US Oncology Reports Third Quarter 2008 Results 16Health News:US Oncology Reports Third Quarter 2008 Results 17Health News:US Oncology Reports Third Quarter 2008 Results 18Health News:US Oncology Reports Third Quarter 2008 Results 19Health News:US Oncology Reports Third Quarter 2008 Results 20Health News:US Oncology Reports Third Quarter 2008 Results 21Health News:US Oncology Reports Third Quarter 2008 Results 22Health News:US Oncology Reports Third Quarter 2008 Results 23Health News:MedQuist Introduces SpeechQ for Radiology Integrated with RadWorkFlow 2Health News:MedQuist Introduces SpeechQ for Radiology Integrated with RadWorkFlow 3Health News:Global Med Technologies(R), Inc.'s Inlog Subsidiary Licenses Its Leading Laboratory Information System to Gabriel Martin Hospital of Saint-Paul de la Reunion 2Health News:Global Med Technologies(R), Inc.'s Inlog Subsidiary Licenses Its Leading Laboratory Information System to Gabriel Martin Hospital of Saint-Paul de la Reunion 3Health News:Global Med Technologies(R), Inc.'s Inlog Subsidiary Licenses Its Leading Laboratory Information System to Gabriel Martin Hospital of Saint-Paul de la Reunion 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: